A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

Status: Recruiting

Eligibility Criteria

Sex: Female
Age: 18 Years and over

Inclusion Criteria:
- recurrent or persistent endometrial carcinoma, which is refractory to curative therapy or established treatments - following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.); NOTE: clear cell histology is excluded - must have had one prior chemotherapeutic regimen for management of endometrial carcinoma - Body weight > 30 kg - able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption

Exclusion Criteria:
- Prior enrollment into a clinical trial including cediranib or olaparib; Note: prior bevacizumab is not an exclusion criterion - Pregnant women are excluded

Conditions & Interventions

Interventions:
Drug: Capivasertib, Drug: Cediranib, Drug: Cediranib Maleate, Biological: Durvalumab, Drug: Olaparib

Conditions:
Cancer

Keywords:
Endometrial Cancer

More Information

Description: This study uses different drug combinations to treat women who have endometrial cancer that has come back or has not responded to treatment. The drugs have different ways of stopping the growth of tumor cells and we are looking to see if different combinations are more effective.

Contact(s): Kristen Nelson - knelso65@fairview.org
Principal Investigator: Edward Greeno, M.D.
IRB Number: MMCORC011
System ID: MMCORC011

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.